Archives
-
ADRA2A Activation Sensitizes Ovarian Cancer to Carboplatin
2026-09-17
Albanna and colleagues used an unbiased repurposing screen to identify ADRA2A agonism as a pharmacological route for increasing carboplatin sensitivity in ovarian cancer cell models. Validation with three agonists, multiple cell lines, independent viability assays, and ADRA2A overexpression supports a target-centered hypothesis, while remaining preclinical and in vitro.
-
Atorvastatin: Designing Mechanism-First Assays
2026-09-17
Atorvastatin is more than an HMG-CoA reductase inhibitor: it is a mechanistic probe connecting mevalonate flux, vascular signaling, and ferroptosis. This guide translates recent hepatocellular carcinoma evidence into assay-design decisions, controls, and interpretation strategies.
-
EZ Cap EGFP mRNA 5-moUTP: Applied Workflow
2026-09-16
Use this enhanced green fluorescent protein mRNA as a practical benchmark for delivery, translation, viability, and imaging experiments. Its Cap 1 structure, 5-moUTP modification, and approximately 100-nucleotide poly(A) tail support a controlled way to compare formulations before advancing to therapeutic or functional mRNA cargos.
-
ICAA Disrupts HBV Replication via HO-1 and ROS
2026-09-16
The reference study shows that isochlorogenic acid A (ICAA) suppresses hepatitis B virus replication through multiple effects involving HO-1-associated ROS modulation, reduced viral nucleic acids, and defective particle morphogenesis. Its integrated cellular and particle-level design provides a framework for separating effects on cccDNA-linked replication from defects in capsid formation and envelopment.
-
Iterative Discovery of TAS2R14 Ligands
2026-09-15
The reference study presents an iterative experimental–computational strategy for finding agonists and antagonists of TAS2R14, a highly promiscuous bitter taste GPCR without an experimental structure. By combining cell-based screening, synthesis of flufenamic acid derivatives, and progressive binding-pocket refinement, the authors substantially expand the chemical toolkit available for studying this receptor.
-
Arachidonic Acid Accelerates Vaccine Immunity
2026-09-15
The reference study shows that dietary arachidonic acid can strengthen rabies vaccine-induced humoral immunity in mice and accelerate protective neutralizing antibody responses in human volunteers. Its mechanistic contribution is the identification of a lymph node ARA–PGI2–cAMP/PKA pathway that supports CD86 expression and activation-induced cytidine deaminase in B cells.
-
Fluo-4 AM for Podocyte Calcium Signaling Assays
2026-09-14
Learn how Fluo-4 AM converts transient Ca2+ changes into actionable readouts for podocyte and diabetic nephropathy research. This workflow emphasizes matched controls, live-cell kinetics, assay normalization, and troubleshooting for mechanistic calcium signaling studies.
-
AAL-993 and the Next Logic of Tumor Angiogenesis
2026-09-14
A mechanistic and translational framework for using AAL-993 as a selective VEGF receptor inhibitor in tumor angiogenesis research, while integrating pathway-level insights from glioma studies without overstating what the evidence proves.
-
TPPU as a Mechanistic Probe of Epoxide Signaling
2026-09-13
TPPU is a potent soluble epoxide hydrolase inhibitor for dissecting fatty acid epoxide signaling, inflammatory pain, and bone-remodeling biology. This article presents an assay-centered framework that separates target engagement from downstream Nrf2 and osteoclast phenotypes.
-
Chloroquine, MrgprA3, and Sensory Research
2026-09-12
Chloroquine is more than an autophagy inhibitor: it is also a mechanistically informative pruritogen through MrgprA3-positive sensory neurons. This article translates new chronic-dermatitis findings into practical assay decisions while distinguishing sensory, immune, antiviral, and anticancer readouts.
-
Lipo3K Transfection Reagent: Assay Guide
2026-09-11
Learn how Lipo3K Transfection Reagent, SKU K2705, can help laboratories manage transfection-related variability in viability, proliferation, and cytotoxicity assays. This scenario-based guide covers difficult-to-transfect cells, DNA and siRNA workflows, protocol timing, data interpretation, and practical reagent selection.
-
Adiponectin, TLR4, and Cognitive Protection After Surgery
2026-09-11
This reference study shows that adiponectin pretreatment reduces splenectomy-associated cognitive deficits in aged rats, with parallel suppression of hippocampal TLR4/MyD88/NF-κB signaling, oxidative stress, and microglial inflammation. Pharmacological inhibition and activation of TLR4 strengthen the proposed mechanism while also highlighting the need for further validation in clinically relevant perioperative neurocognitive disorder models.
-
Regorafenib: From Kinase Blockade to RRM2
2026-09-10
Regorafenib research is moving beyond broad kinase inhibition toward mechanistic interpretation of RRM2 and ERK/E2F3 signaling. This guide connects melanoma findings with angiogenesis research, migration assays, and tumor xenograft models.
-
GW4064 for FXR Signaling: Applied Workflows
2026-09-10
GW4064 is a potent, non-steroidal FXR agonist for separating receptor-driven effects from broader stress responses in lipid, bile acid, and fibrosis models. This guide translates recent LX-2 cell findings into practical dosing, controls, readouts, and troubleshooting strategies.
-
Cand2, Ubiquitination, and Fungal Pathogenicity
2026-09-09
The reference study identifies MoCand2 as a conserved fungal inhibitor of Cullin-RING ligase-mediated ubiquitination and connects this activity to autophagy control in Magnaporthe oryzae. Its findings show that excessive ubiquitination alters MoTor and MoAtg6 regulation, enhancing autophagy while impairing fungal development, stress adaptation, and rice-infection capacity.